기립불능증으로 발현한 다발골수종과 연관된 아밀로이드증
Myeloma-associated Amyloidosis Presenting as Orthostatic Intolerance
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Amyloidosis is a systemic disorder associated with clonal plasma cell dyscrasia. Nephrotic syndrome, congestive heart failure, autonomic and peripheral neuropathy is often associated features in amyloidosis. Early diagnosis is most important because of different prognosis by stage. The diagnosis can be delayed since symptoms of amyloidosis may vary or nonspecific. We describe a patient of myeloma-associated amyloidosis, who showed orthostatic intolerance as the first symptom of the disease. (Korean J Clin Neurophysiol 2015;17:24-27)
Abstract
Amyloidosis is a systemic disorder associated with clonal plasma cell dyscrasia. Nephrotic syndrome, congestive heart failure, autonomic and peripheral neuropathy is often associated features in amyloidosis. Early diagnosis is most important because of different prognosis by stage. The diagnosis can be delayed since symptoms of amyloidosis may vary or nonspecific. We describe a patient of myeloma-associated amyloidosis, who showed orthostatic intolerance as the first symptom of the disease. (Korean J Clin Neurophysiol 2015;17:24-27)
참고문헌 (8)
- Hawkins PN., "Amyloidosis", Blood Rev, 9, pp.135~142 (1995)
- Wang AK, "Patterns of neuropathy and autonomic failure in patients with amyloidosis", Mayo Clin Proc, 83, pp.1226~1230 (2008)
- Duston MA, "Peripheral neuropathy as an early marker of AL amyloidosis", Arch Intern Med, 149, pp.358~360 (1989)
- Low, A. P, "Cinical autonomic disorders", pp.387~ (2008), Williams & Wilkins
- Mahmood S, "Update on treatment of light chain amyloidosis", Haematologica, 99, pp.209~221 (2014)
- Kumar S, "Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements", J Clin Oncol, 30, pp.989~995 (2012)
- Chan J, "Amyloid light-chain amyloidosis, myeloma and autonomic neuropathy", Grand Rounds, 11, pp.56~59 (2011)
- "Assessment: Clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology", Neurology, 46, pp.873~880 (1996)